Analyst Price Targets — DNTH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 6, 2026 10:07 am | — | H.C. Wainwright | $158.00 | $112.50 | TheFly | Dianthus price target raised to $158 from $130 at H.C. Wainwright |
| August 5, 2026 11:58 am | — | Wedbush | $122.00 | $111.27 | TheFly | Dianthus price target raised to $122 from $105 at Wedbush |
| August 5, 2026 10:39 am | Ryan Deschner | Raymond James | $131.00 | $110.40 | StreetInsider | Dianthus Therapeutics (DNTH) PT Raised to $131 at Raymond James |
| June 10, 2026 7:53 pm | — | Jefferies | $132.00 | $76.42 | TheFly | Dianthus price target raised to $132 from $110 at Jefferies |
| May 11, 2026 12:04 pm | Gavin Clark-Gartner | Evercore ISI | $120.00 | $88.45 | TheFly | Dianthus price target lowered to $120 from $122 at Evercore ISI |
| May 6, 2026 12:48 pm | — | Raymond James | $125.00 | $87.83 | TheFly | Dianthus price target raised to $125 from $123 at Raymond James |
| April 8, 2026 8:38 pm | Andy Chen | Wolfe Research | $98.00 | $87.48 | TheFly | Dianthus initiated with an Outperform at Wolfe Research |
| March 9, 2026 7:56 pm | Maury Raycroft | UBS | $98.00 | $79.23 | TheFly | Dianthus price target raised to $98 from $81 at Jefferies |
| March 9, 2026 7:51 pm | Maury Raycroft | Jefferies | $98.00 | $79.23 | StreetInsider | Dianthus Therapeutics (DNTH) PT Raised to $98 at Jefferies |
| March 9, 2026 4:36 pm | — | Robert W. Baird | $132.00 | $79.23 | TheFly | Dianthus price target raised to $132 from $67 at Baird |
Latest News for DNTH
NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in three investor conferences.
Alyeska Investment Group L.P. increased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 188.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 150,592 shares of the company's stock after buying an additional 98,345 shares during the
Dianthus Therapeutics is building a neuromuscular franchise around claseprubart, differentiated by clinical profile and financial independence. DNTH holds ~$1.2B in cash and investments, supporting multiple late-stage programs and reducing funding event risk through 2030. Claseprubart's dosing convenience, pathway selectivity, and strong early data set it apart amid evolving competitive dynamics, especially after…
Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.
California State Teachers Retirement System boosted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 155.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,584 shares of the company's stock after buying an additional
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DNTH.
U.S. House Trading
No House trades found for DNTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.